Expert Guidance. Proven Leadership. Optimized Outcomes.
Based in Pennsylvania | Serving biotech and pharmaceutical clients globally
Switchback BioStrategy Group provides high-impact strategic guidance and project leadership to biotechnology and pharmaceutical innovators advancing assets from preclinical discovery through global commercialization.
About Switchback BioStrategy Group
Switchback BioStrategy Group is a specialized consulting firm dedicated to navigating the complexities of drug development and optimizing portfolio value. We partner with biotechnology and pharmaceutical companies to deliver cross-functional strategic expertise, rigorous project management, and operational excellence that accelerate timelines and reduce risk.
Founded on the belief that the best development strategies combine deep scientific insight with disciplined execution, we help our clients make confident decisions at every stage of the asset lifecycle.
Led by a Seasoned Industry Leader
Michael Miernicki, Ph.D. Principal & Founder
Dr. Michael Miernicki is a veteran biotechnology and pharmaceutical executive with nearly four decades of success driving global drug development and process transformation. Combining a rigorous background in neuroscience and statistics with senior vice president leadership roles, he brings a unique cross-functional lens to every engagement.
Throughout his career at leading innovators — Amgen, Bristol-Myers Squibb, Johnson & Johnson — as well as private and publicly-funded biotech companies (Perspective Therapeutics, KBP Biosciences, Drais Pharmaceuticals, GPC Biotech, FIDIA Pharmaceuticals) and premier global CROs (ICON, Worldwide Clinical Trials), Dr. Miernicki has built elite project management infrastructures, scaled cross-functional teams, and optimized R&D portfolios.
He specializes in translating complex clinical data into robust, risk-mitigated corporate strategies that deliver measurable results.
Careers
What Sets Us Apart
Driven by a unique combination of deep roots in multiple therapeutic areas, rigorous statistical precision, and decades of executive asset management.
A rare combination of neuroscience, statistics, and senior executive experience across big pharma, biotech, and CRO environments.
Advanced portfolio valuation, statistical precision, and clear risk-mitigation frameworks that support funding, licensing, and regulatory success.
We design and implement governance structures, operational turnarounds, and high-performing development organizations — not just advise on them.
Extensive Therapeutic Footprint
We bring proven global development and strategy experience across a wide range of high-stakes therapeutic areas:
Biosimilars, Cardiovascular, CNS & Neurodegenerative, Dermatology, Endocrinology, Gastroenterology, General Medicine, Immunology, Infectious Diseases, Metabolic, Neuroscience, Oncology, Radiopharmaceuticals, Respiratory, Rheumatology, Urology.
Our Approach
At Switchback BioStrategy Group, we go beyond standard consulting. We become an extension of your team — providing executive-level project leadership, strategic clarity, and operational infrastructure that drives efficient milestone execution and maximizes asset value.
We are committed to partnership, integrity, and delivering practical, actionable solutions tailored to each client’s unique needs.